Skip to main content

 

Interested in participating?

What is PrEP (pre-exposure prophylaxis)?

HIV stands for human immunodeficiency virus. It weakens a person’s immune system by destroying important cells that fight disease and infection. There is currently no effective cure for HIV. However, with proper medical care, HIV can be controlled and even prevented.

HIV PrEP are medications used to reduce the risk of acquiring HIV. There are several FDA-approved PrEP medications, all of which require a person to take a pill by mouth once a day. These clinical research studies are exploring other options:

Would a pill taken by month once a month be effective in preventing HIV?
Would an injection given twice a year be effective in preventing HIV?

We have lots of tools to help us prevent HIV

Condoms
Treatment
Needle Exchange
Once-a-day oral PrEP

Unfortunately, these do not work for everyone. We need more options to ensure everyone has access to HIV prevention tools that work for them.

Studies currently enrolling:

Merck8591- 022

“Evaluation of the efficacy and safety of oral Islatravir as a pre-exposure prophylaxis in cisgender women at high risk for HIV-1 Infection”

Are you HIV-negative, curious about prevention research? You may be interested in participating in our clinical study for an HIV preventative medication for cisgender women. Participants will receive study medication & clinical study-related care at no cost. Participants can earn up to $2,100 by participating in this clinical trial.

Merck8591- 024

“Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as pre-exposure prophylaxis in cisgender men and transgender women who have sex with men and are at high risk for HIV-1”

Are you HIV-negative, curious about prevention research? You may be interested in participating in our clinical study for an HIV preventative medication. The purpose of our research is to study once-monthly PrEP vs. once-daily PrEP. This study is open to gay and bisexual men, as well as, transgender women. Participants will receive study medication & clinical study-related care at no cost. Participants can earn up to $1,600 by participating in this clinical trial.

GS-US-528-9023

“Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People ≥ 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection”

Are you HIV-negative, curious about prevention research? You may be interested in participating in our clinical study for an HIV preventative medication. The purpose of our research is to study once-monthly PrEP compared to long-lasting (twice-yearly) injection. This study is open to gay and bisexual men, as well as, transgender women. Participants will be compensated for time and travel.


Steps to participate in clinical research 

1. Prescreen

2. Enrollment

3. Study Intervention 

4. Follow-up

 


Ready for PrEP (pre-exposure prophylaxis)?

 

 

Join Now